Quick Facts: Uses of Diltiazem

• Helps manage high blood pressure (hypertension).
• Assists in the management of chronic stable angina (chest discomfort).
• Used for the care of angina resulting from coronary artery spasm (Prinzmetal's or variant angina).
• Indicated for the temporary control of a rapid heart rate in certain atrial rhythm concerns, such as atrial fibrillation or atrial flutter.

---

Diltiazem is a prescription medication utilized in therapeutic regimens for various cardiovascular concerns. The primary applications involve addressing high blood pressure, also referred to as hypertension. Appropriate management of elevated blood pressure is a key component of comprehensive care and is associated with a reduced potential for serious events like stroke or heart attack.

The medication is also indicated for the management of angina, or chest discomfort. Specifically, it helps in the care of chronic stable angina and is a therapeutic option for variant angina, which is chest discomfort resulting from coronary artery spasm. Diltiazem is further used in a hospital setting for the temporary control of a rapid ventricular rate associated with specific atrial rhythm disturbances, including atrial fibrillation and atrial flutter.

This medication is typically employed as part of a wider treatment approach that may include lifestyle modifications.

Official Eligibility and Restrictions for Дилтиазем (Diltiazem)

The use of Diltiazem is strictly defined by regulatory documents, distinguishing between absolute prohibitions, conditional use, and non-established populations.

Eligibility Scope	Status (Official Regulatory Statement)
Absolute Contraindications	Prohibited in patients with sick sinus syndrome or second-/third-degree AV block (unless a functioning pacemaker is present); severe hypotension (systolic < 90 mmHg); cardiogenic shock; acute myocardial infarction with pulmonary congestion; accessory bypass tract syndromes (e.g., Wolff-Parkinson-White); and known hypersensitivity to the drug.
Age Restriction	Safety and effectiveness have not been established in the pediatric population (children and adolescents). Use in this group is not recommended [2.2, 2.7]. Older adults may require cautious dose selection due to increased likelihood of reduced organ function [2.4].
Conditional Use	Caution is mandatory for patients with impaired hepatic or renal function and those with reduced left ventricular function or congestive heart failure [1.1, 2.1]. Close observation is necessary for patients with first-degree AV block [3.1].
Pregnancy/Lactation	Use in pregnancy is only recommended if the potential benefit justifies the potential risk to the fetus [1.4]. Diltiazem is excreted in human milk, requiring an alternative method of infant feeding if the drug is deemed essential for the mother [1.4].

This framework ensures that only adult patients without documented contraindications are considered eligible for Diltiazem, while populations with specific cardiac conditions or organ impairment are either excluded or require intensive monitoring as defined in the official prescribing information.

Interactions with other medicines and products

Diltiazem is a moderate inhibitor of the CYP3A4 enzyme system and is also a substrate of this system. This dual activity is the primary basis for its extensive drug interaction profile. Co-administration of Diltiazem with medicines that are substrates of CYP3A4, such as certain statins (e.g., Simvastatin, Lovastatin) and immunosuppressants (e.g., Cyclosporine, Tacrolimus), can significantly increase the concentration and effects of these co-administered drugs. This often necessitates dosage reduction of the partner drug to mitigate the risk of adverse reactions, such as muscle toxicity with statins.

Simultaneous use of Diltiazem with medicines that also affect cardiac function—specifically beta-blockers or digitalis—requires caution due to the risk of additive effects, potentially leading to slow heartbeat or heart block. Certain medicines are contraindicated for use with Diltiazem due to severe interaction risks, including Ivabradine (due to excessive heart rate reduction) and Lomitapide (due to risk of liver enzyme elevation).

Conversely, agents that induce CYP3A4 (e.g., Rifampin) can decrease the level of Diltiazem in the body, potentially reducing its effectiveness. Additionally, patients are advised to avoid simultaneous alcohol consumption with the extended-release formulation of Diltiazem, as this can increase the rate and extent of its absorption.

How Дилтиазем Works

Direct Blockade of L-Type Calcium Channels

Дилтиазем’s core action involves the precise blockade of L-type Voltage-Dependent Calcium Channels in cardiovascular cells. This molecular mechanism directly inhibits the influx of extracellular calcium ions ( Ca^2+), which are required for the contraction of muscle and the firing of electrical signals in the heart.

---

Control of Cardiac Electrical Rhythm

By reducing Ca^2+ entry, the drug modulates the electrical timing in the specialized heart tissues (SA and AV nodes). This results in a negative chronotropic effect (slowing of heart rate) and a negative dromotropic effect (slowing of electrical conduction), which results in modulation of the rate and rhythm of the cardiac cycle.

---

Relaxation of Vascular Smooth Muscle

The blockade of Ca^2+ influx into peripheral and coronary arterial walls prevents the sustained contraction of vascular smooth muscle cells. This physiological cascade leads to arterial vasodilation and a reduction in systemic vascular resistance, which consequently reduces the force required for ventricular ejection (afterload).

Official Administration Guidelines

Diltiazem is officially administered via two distinct routes, depending on the therapeutic goal: Oral (tablets and capsules) for long-term chronic treatment, and Intravenous (IV) solution for temporary, acute rate control, which is strictly limited to a supervised setting.

---

Dosage and Schedule

Administration Type	Starting Dose (Adult)	Typical Frequency/Duration
Immediate-Release (IR) Oral	30 mg	Four times a day (QID). Dose may be gradually titrated over 1–2 days.
Extended-Release (ER) Oral	180 mg to 240 mg	Once daily (QD). Titration intervals are typically 7 to 14 days.
Intravenous (IV) Bolus	0.25 mg/kg over 2 minutes	May be followed by a second bolus of 0.35 mg/kg after 15 minutes.
Intravenous (IV) Infusion	5 mg/hour to 15 mg/hour	Continuous infusion following bolus, typically not exceeding 24 hours.

---

Preparation and Use Constraints

Oral Administration: Extended-release tablets and capsules must be swallowed whole and must not be crushed, chewed, or divided to maintain their release characteristics. Administration may be done without regard to food. If a dose is missed, the practice is to take the next scheduled dose at the usual time and not double the dose to compensate.

Intravenous Administration: The IV solution requires dilution prior to continuous infusion and must be administered with continuous monitoring of the patient’s cardiac activity and blood pressure. For specific populations, treatment in patients with severe hepatic or renal impairment is initiated with a lower dose and titrated slowly due to the drug's metabolism.

Diltiazem: Recent Clinical Evidence

Clinical evidence on diltiazem, a non-dihydropyridine calcium channel blocker, continues to support its use for hypertension, chronic stable angina, and certain atrial arrhythmias.

Efficacy in Primary Cardiac Conditions

Studies across various cardiovascular patient groups show that diltiazem is associated with reducing heart rate and blood pressure, which collectively decreases the heart's workload and oxygen demand. Evidence includes:

• Chronic Stable Angina: Research indicates that diltiazem therapy can increase exercise tolerance and reduce the frequency of angina episodes, likely through its dilatory effect on coronary arteries. Comparative trials suggest it has a similar effectiveness to other standard agents, such as diuretics or beta-blockers, in managing chronic exertional angina.
• Atrial Arrhythmias: Intravenous diltiazem has demonstrated rapid effectiveness for temporarily controlling the rapid ventricular rate in patients with atrial fibrillation or atrial flutter, often achieving the maximum effect within minutes of administration.

---

Emerging Research and Specific Populations

More recent randomized controlled trials (RCTs) have focused on specific patient subgroups and outcomes:

• ANOCA (Angina with Non-Obstructive Coronary Artery Disease): The EDIT-CMD trial investigated the effect of diltiazem in patients with ANOCA and evidence of coronary vasomotor dysfunction. The study reported that diltiazem did not significantly improve overall coronary vasomotor dysfunction, symptoms, or quality of life compared to placebo over six weeks. However, the trial did suggest that diltiazem therapy reduced the prevalence of epicardial spasm in this group.

Condition	Research Finding
Hypertension	Consistently shown to be effective as a first-line or combination agent for lowering blood pressure.
Coronary Artery Spasm	Highly effective in case reports for the acute reversal of spasm, including those that induce complete atrioventricular block.

Common questions about Дилтиазем (FAQ)

Q: Is Diltiazem safe to take during pregnancy?

Official regulatory documents state that Diltiazem is recommended for use during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. The safety and effectiveness of the drug have not been fully established through controlled human studies during pregnancy. Regulatory labeling indicates that use during pregnancy requires careful consideration by a healthcare professional.

---

Q: What is the maximum daily dose of oral Diltiazem?

Official prescribing information defines the maximum recommended daily doses for oral Diltiazem. For extended-release forms, the maximum typical dose is up to 540 mg once daily for hypertension, and up to 360 mg once daily for chronic stable angina. A patient's exact dose is determined by their prescribing healthcare professional.

---

Q: Does Diltiazem interact with all statins?

Diltiazem is a moderate inhibitor of the CYP3A4 enzyme system, which can slow the breakdown of other medicines, including certain statins (such as Simvastatin and Lovastatin). This action can increase the concentration of these statins in the blood and may increase the risk of side effects like muscle toxicity. The interaction is limited to certain statins, and specific guidance from a healthcare provider is necessary.

---

Q: How is Diltiazem eliminated from the body?

According to official product information, Diltiazem is extensively metabolized (chemically processed) by the liver. Following this metabolism, the drug and its components are primarily eliminated from the body through the urine. Official information notes that the drug’s metabolism and excretion are a key consideration for patients with severe liver or kidney impairment.

---

Q: What foods or drinks should I avoid while on Diltiazem?

Regulatory information indicates that consumption of grapefruit or grapefruit juice may lead to increased levels of Diltiazem in the blood and may raise the risk of side effects. Additionally, official labeling advises avoiding alcohol consumption, particularly when taking the extended-release formulation of Diltiazem.

---

Q: Does Diltiazem cause weight gain?

Weight gain is not commonly listed as an adverse event in official clinical trial data for Diltiazem. However, peripheral edema (swelling in the hands, ankles, or feet due to fluid retention) is a commonly reported side effect. This fluid retention is a common side effect and should be discussed with a healthcare provider.

---

Q: Can I crush the Diltiazem tablet to mix with food if I have trouble swallowing?

Official administration guidelines state that extended-release tablets and capsules must be swallowed whole and should not be crushed, chewed, or divided. The integrity of the tablet must be maintained to ensure the correct release of the medication over time.

Storage and Disposal of Diltiazem

Official regulatory guidelines define specific conditions for storing Diltiazem to maintain its stability. Oral tablets and capsules must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F). The medication must be kept in a tight, light-resistant container and protected from excessive humidity.

Special Conditions

Injectable Diltiazem solutions often require refrigeration (2 C to 8 C), and all formulations are explicitly labeled with the instruction: Do not freeze. After reconstitution, the injectable powder solution is typically stable for only 24 hours. For safety, the drug must always be stored out of reach of children.

Disposal

All unused or expired Diltiazem products, including any unused portions of the injectable solution, must be disposed of according to local regulations.